DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161500

Open label study to assess the safety and efficacy of cinacalcet in refractory hyperparathyroidism with chronic renal failure

Reema Thottol, M. Sreelatha, PV Narayanan

Abstract


Background: Secondary hyperparathyroidism a common consequence of chronic kidney disease is associated with many complications like renal osteodystrophy, vascular and soft tissue calcification. This study is to assess the safety and efficacy of Cinacalcet a calcimimetic drug in patients with refractory hyperparathyroidism due to chronic renal failure.

Methods: Patients with chronic kidney disease stage 5 on maintenance haemodialysis diagnosed to have refractory hyperparathyroidism who do not attain the target range for hyper-parathyroid indicators serum PTH ≤300, Serum Ca (8.4-9.5), serum phosphorous (3.5-5.5) with the use of calcitriol and phosphate binders were included in the study. Twenty patients satisfying the case definition of refractory hyperparathyroidism due to chronic renal failure received 30mg Cinacalcet therapy. Total duration of treatment was 6 weeks. Standard serum calcium, serum phosphorous, PTH was assessed before and after 6 weeks.

Results: Cinacalcet significantly reduces serum PTH level when results were compared by paired t test. P=0.016 <0.05 (significant). No statistically significant reduction in serum calcium and phosphorous. Serum calcium P value=0.599>0.05, serum phosphorous P=0.132>0.05. In this study after overall assessment.

Conclusions: Cinacalcet is more efficacious and safe in treating refractory hyperparathyroidism due to chronic renal failure.


Keywords


Hyperparathyroidism, Cinacalcet, Calcitriol, Phosphate binders, Calcimimetic, Parathormone

Full Text:

PDF

References


Al-Hilali N, Hussain N, Kawy YA, Al-Azmi M. A novel dose regimen of cinacalcet is the treatment of severe hyper parathyroidism in haemodialysis patients. Saudi Journal of kidney disease and transplantation. 2011;22(3);448-55.

Sherier RW, Gottschalk C. Diseases of kidney vol. III, 6th Edi.; 2490-2680.

Block GA, Martin KJ, Francisco AM, Turnen SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyrodism in patients receiving haemodialysis NEJM. 2004;350:1516-25.

Harrisons internal medicine 16th edition, Chapter; 261:1653.

Mircescu G. Dr Carol Davila teaching hospital of nephrology, surgical or medical therapy for severe hyperparathyroidism of chronic kidney diseases, an appraisal of current practice guidelines. Acta edocrinologica 2010;4:541-76.

Hruska KA, levi M, Slatopolsky E. Disorders of phosphorous, calcicum and magnesium metabolism. In: Shrier RW. Disease of kidney and urinary tract. 8th edi.; 2007:3:2295-2335.

Martin KJ, Gonzalez EA, slatopolsky E. Renal osteodystrophy. In: Brenner and Rectors. The Kidney.7th edi.; 2004:2:2256-2293.

Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, et al. KDOQI US commentary on the 2009 KDIGO clinical practice guidelines for the diagnosis evaluation and treatment of CKD-mineral and bone disorder. Am J Kidney Disease. 2010;55(5):773-799.

Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. Clin J Am Soc Nephrol. 2007:18;875-85.

Davidsons principles and practice of medicine 19th edi.; 714-718.

Friedman PA. Agents affecting mineral ion homeostasis and bone turnover. In: Goodman and Gillmans pharmacological Basis of Therapeutics 12th edi.; 2011:1275-1302.

Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dales pharmacology. 6th edi.; 461-46.

Satoskar RS, Bandarkar SD, Rege NN. Pharmacology and pharmacotherapeutics. 20th edi.; 975-990.

Robbins and Cotran Pathologic basis of disease 7th edi.; 1184-1188.

Goodman WG, Belin TR, Salusky IB. In vivo assessments of calcium-regulated parathyroid hormone release in secondary hyperparathyroidism. Kidney International. 1996;50:1834-44.

Essentials of medical pharmacology K.D. Thripathi, 6th edi.; 208:1:325-332.

Backle DD. Agents that affect bone mineral homeostasis. In: Bertram G, Katzung, basic clinical pharmacology 11th edi.; 2009:1:753-765.

Dong BJ. Cinacalcet an oral calcimimetic agent for the management of hyperparathyroidism, Clinical Therapeutics. 2005;27:1725-51.

Brommage D, Gallgana C. Role of conacalcet in treating secondary hyperparathyroidism. Nephrol Nurs J. 2005;32(2):229-31.

Text book of biochemistry for medical students, DM Vasudevan and Sreekumari 4th edi.; 2005:300-302.

Harpers illustrated Biochemistry 27th edi.; 457-458.

Review of medical physiology William F Ganong 22nd edi.; 190-392

Calcimimetic agents. In: Brenner and Rectors, The kidney 8th edi.; 2008:1904-1929.

Torres PU. Clinical experience with cinacalcet HCL. Nephrol Dial Transplant. 2004;19(5):27-33.

Skorecki K, Green J, Brenner BM. Chronic renal failure. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editorsHarrisons Internal Medicine 15th edi. New York: McGraw-Hill; 2001:1551-1562.

Valle C, Rodriguez M, Santamaria R, Almaden Y. Cincalcet reduces the set point of PTH-calcium curve. Clin J Am Soc Nephrol. 2008;19:2430-36.

Kaczirek K, Prager G, Riss P, Wunderer G, Asari R, Scheuba C, et al. Novel parathyroid hormone monitoring in renal hyper parathyroidism. Arch Surg. 2006;141:129-34.

Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. NEJM. 2004;350:1516-25.

Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet treatment algorithm for secondary hyperparathyrodism. Clin J Am Soc Nephrol. 2008;3:136-45.

Drueke TB, Mc Caron DA. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. N Engl J Med. 2003;349(5):496-9.

Torres PU. Cinacalcet Hcl; a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr. 2006;16(3):253-8.

Block GA, Martin KJ, Francisco AM, Turnen SA, Avram MV, Suranyi MG, et al. Cinacalcet for secondary hyperparathyrodism in patients receiving haemodialysis. NEJM. 2004;350:1516-25.

Berg JL, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB. Cincalcet Hcl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal diaysis. J Am Soc Nephrol. 2005;16:800-7.

Zitt E, Rix M, Torres PU, Fouque D, Jacobson HS, Frankpetavy. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyper parathyroidism following parathyroidectomy; results of ECHO study. Nephrology dialysis Transplant. 2010;1-6.

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end stage renal disease on maintenance dialysis therapy national institue of health and clinical excellence (NICE) technology appraisal guidelines; 2007:117.

Jadoul M, Banos A, Zani VJ, Hercz G. The effects of discontinuing Cinacalcet at the time of kidney transplantation nephrology dialysis transplantation plus. 2010;3:37-41.

Tomasello S. Secondary hyperparathyroidism and chronic kidney disease. Journal American diabetes association. 2008;21(1):19-25.

Elder G. Use of calcimimetic drug CARI guidelines caring for Australians with renal impairment. 2006:1-11.

William S, Malatesta K, Norris K. Vitamin D and kidney disease, ethnicity and disease. Autuman. 2009;19:S5-11.